Trial of Cell Therapy to Raise HbF Levels Showing Potential, But Sanofi Leaving

Trial of Cell Therapy to Raise HbF Levels Showing Potential, But Sanofi Leaving

316161

Trial of Cell Therapy to Raise HbF Levels Showing Potential, But Sanofi Leaving

Sangamo Therapeutics is assuming all rights to SAR445136, an investigational gene-edited cell therapy co-developed with Sanofi and now in a Phase 1/2 trial in adults with severe sickle cell disease (SCD). Early trial data support the therapy’s safety and tolerability, and its effectiveness at raising levels of fetal hemoglobin in patients, the companies have announced. Sanofi had been leading the Phase 1/2 PRECIZN-1 trial (NCT03653247) — with the therapy under that company’s assigned name of BIVV003 — as part…

You must be logged in to read/download the full post.